利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.038 秒)

    Continuously variable transmission device
    1.
    发明申请
    Continuously variable transmission device 有权
    连续可变传动装置

    公开(公告)号：US20070142164A1

    公开(公告)日：2007-06-21

    申请号：US10579183

    申请日：2004-11-11

    申请人： Peter Milner

    发明人： Peter Milner

    IPC分类号： F16H15/38

    CPC分类号： F16H15/52

    摘要： A continuously variable transmission device has planetary members (23) in rolling contact with radially inner and outer races (12, 14; 36, 37) each comprising axially spaced relatively axially movable parts, and control means (18) for determining the axial separation of the parts (12, 14) of one of the two races, in which the planetary members (23) are connected for drive transmission to an input or output member (30) of the transmission device by connection means which allows the radial position of the planets to vary in response to variation in the axial separation of the parts (12, 14) of the said one of the two races (37), and in which the generatrix of the curved surface (70, 71) of at least one of the races (37) and/or planetary members (23) is non-circular.

    摘要翻译： 一种无级变速传动装置具有与径向内径和外径（12,14; 36,37）滚动接触的行星构件（23），每个径向内和外座圈（12,14; 36,37）均包括轴向间隔开的相对轴向可移动部件，以及控制装置（18），用于确定 两个座圈中的一个的部分（12,14），其中行星构件（23）被连接以通过连接装置通过连接装置驱动传动到传动装置的输入或输出构件（30），所述连接装置允许 行星根据两个座圈（37）中的一个的部件（12,14）的轴向间隔的变化而变化，并且其中曲面（70,71）的母线中的至少一个 种族（37）和/或行星构件（23）是非圆形的。

    Methods of treating or preventing thromboses
    3.
    发明授权
    Methods of treating or preventing thromboses 有权
    治疗或预防血栓形成的方法

    公开(公告)号：US6087375A

    公开(公告)日：2000-07-11

    申请号：US330744

    申请日：1999-06-11

    申请人： Dominique P. Bridon ,  Alan Ezrin ,  Peter Milner

    发明人： Dominique P. Bridon ,  Alan Ezrin ,  Peter Milner

    IPC分类号： C12N5/06 ,  A61K38/00 ,  A61K47/48 ,  A61P7/02 ,  C07K5/068 ,  C07K14/765 ,  C07K16/18 ,  C07D215/04 ,  A61K31/4709 ,  C07D215/06

    CPC分类号： A61K47/48007 ,  A61K47/48238 ,  A61K47/48384

    摘要： Novel compounds comprising chemically reactive intermediates which can react with available reactive functionalities on blood components to form covalent linkages, where the resulting covalently-bound conjugates are found to have thrombin inhibition activity are provided. Specifically, the thrombin inhibitor compounds of the present invention are derivatives of the known thrombin inhibitor argatroban, which can be covalently linked to chemically reactive functionalities on various blood components. The conjugated thrombin inhibitors thereby have extended lifetimes in the bloodstream, as compared to the unconjugated parent drug, and are, therefore, capable of maintaining thrombin inhibitory activity for extended periods of time as compared to the unconjugated parent drug. Also provided herein are methods for inhibiting thrombin activity in vivo comprising administering to the bloodstream of a mammalian host the novel compounds of the present invention.

    摘要翻译： 提供了包含化学反应中间体的新型化合物，其可与血液成分上的可用反应性官能团反应以形成共价键，其中发现所得的共价结合的缀合物具有凝血酶抑制活性。 具体地，本发明的凝血酶抑制剂化合物是已知的凝血酶抑制剂阿加曲班的衍生物，其可以与各种血液成分上的化学反应性官能团共价连接。 与未缀合的母体药物相比，缀合的凝血酶抑制剂在血液中的寿命延长，因此与未缀合的母体药物相比，能够延长凝血酶抑制活性。 本文还提供用于抑制体内凝血酶活性的方法，包括向哺乳动物宿主的血流施用本发明的新化合物。

    Windscreen
    7.
    发明申请
    Windscreen 失效
    挡风玻璃

    公开(公告)号：US20060082891A1

    公开(公告)日：2006-04-20

    申请号：US10501273

    申请日：2003-01-10

    申请人： Peter Milner ,  Kirsten Milner

    发明人： Peter Milner ,  Kirsten Milner

    IPC分类号： G02B3/00 ,  B60J1/00

    CPC分类号： B60J1/02

    摘要： A glazing element (12) for an opening defined by opaque boundaries (13) has an edge region (E) shaped to divert light passing through it in a sense such as to enlarge the field of view through the opening. For this purpose the bounding surfaces (33, 34) of the element (12) diverge towards the edge thereof in the edge region (E). The same effect can be achieved by an element (25) adhered to or otherwise held in position to the surface of the element (12) in the edge region (E).

    摘要翻译： 用于由不透明边界（13）限定的开口的玻璃元件（12）具有形状成使透过它的光偏转的边缘区域（E），从而通过开口扩大视场。 为此，元件（12）的边界表面（33,34）在边缘区域（E）中朝向其边缘发散。 通过附接到边缘区域（E）中的元件（12）的表面上或以其他方式保持在适当位置的元件（25）可以实现相同的效果。

    Anti-obesity agents
    9.
    发明申请
    Anti-obesity agents 失效
    抗肥胖剂

    公开(公告)号：US20050176643A1

    公开(公告)日：2005-08-11

    申请号：US11067556

    申请日：2005-02-25

    申请人： Dominique Bridon ,  Roger Leger ,  Xicai Huang ,  Karen Thibaudeau ,  Martin Robitaille ,  Peter Milner

    发明人： Dominique Bridon ,  Roger Leger ,  Xicai Huang ,  Karen Thibaudeau ,  Martin Robitaille ,  Peter Milner

    IPC分类号： A61K38/17 ,  C07K7/08

    CPC分类号： C07K14/57545 ,  A61K38/00 ,  C07K19/00 ,  C07K2319/01

    摘要： The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.

    摘要翻译： 本发明涉及包含与反应性基团偶联的PYY肽或其功能性衍生物的化合物。 这样的反应性基团能够对血液成分进行反应，与其形成稳定的共价键。 本发明还涉及包含共价键合到血液成分上的化合物的缀合物。 此外，本发明还涉及在患者中增强PYY肽或其功能性衍生物的抗肥胖活性的方法。

    Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use
    10.
    发明申请
    Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use 审中-公开
    用于治疗心律失常的新型对映异构体化合物和使用方法

    公开(公告)号：US20050154216A1

    公开(公告)日：2005-07-14

    申请号：US10989010

    申请日：2004-11-15

    申请人： Pascal Druzgala ,  Peter Milner

    发明人： Pascal Druzgala ,  Peter Milner

    IPC分类号： C07D307/54 ,  C07D307/80 ,  C07D37/80

    CPC分类号： C07D307/54 ,  C07D307/80

    摘要： The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The enantiomerically purified compounds, and compositions of these compounds, exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats, as compared to racemic mixtures of the compounds.

    摘要翻译： 本发明涉及新颖的对映异构体纯的化合物和包含该化合物的组合物，用于治疗心律失常。 本发明还涉及制备和纯化化合物的方法。 与化合物的外消旋混合物相比，对映异构体纯化的化合物和这些化合物的组合物显示出意想不到的和有利的特征，例如显着优异的降低或抑制心室过早搏动的能力。